CrossLinker: Aligning Relational and Sequential Contexts for Drug-Target Interaction Prediction in Cold-Start and...

Area of Science:

• Bioinformatics
• Computational Chemistry
• Drug Discovery

Background:

• Accurate drug-target interaction (DTI) prediction is crucial for efficient drug development.
• Existing representation learning methods show promise but struggle with cold-start and few-shot scenarios involving novel drugs or proteins.
• Addressing the challenge of limited data and unseen entities is vital for advancing DTI prediction.

Purpose of the Study:

• To propose a novel DTI prediction framework designed to enhance generalization in low-data and unseen entity settings.
• To improve the accuracy and robustness of DTI prediction models, particularly in challenging cold-start and few-shot scenarios.
• To leverage fine-grained local features and cross-attention mechanisms for more effective DTI prediction.

Main Methods:

• Developed a novel DTI prediction framework incorporating a link-based contrastive learning strategy.
• Implemented a strategy that aligns fine-grained local features from sequence and relational data, rather than global entity features.
• Introduced a link-based cross-attention mechanism to capture contextual features specific to drug-protein pairs.
• Evaluated the model on cold-start and few-shot datasets with unseen drugs or proteins.

Main Results:

• The proposed model significantly outperformed state-of-the-art (SOTA) methods on cold-start and few-shot DTI prediction tasks.
• Demonstrated superior performance compared to current approaches even in conventional data-rich settings.
• The link-based contrastive learning and cross-attention mechanisms effectively improved generalization for unseen entities.

Conclusions:

• The novel framework provides a significant advancement in DTI prediction, especially for scenarios with limited data or novel entities.
• The approach enhances model generalization and accuracy, offering a more reliable tool for drug discovery pipelines.
• This work paves the way for more effective computational drug development by improving the prediction of drug-target interactions.